ITMI20030237A1 - Uso della conglutina di lupino per il trattamento del - Google Patents

Uso della conglutina di lupino per il trattamento del

Info

Publication number
ITMI20030237A1
ITMI20030237A1 IT000237A ITMI20030237A ITMI20030237A1 IT MI20030237 A1 ITMI20030237 A1 IT MI20030237A1 IT 000237 A IT000237 A IT 000237A IT MI20030237 A ITMI20030237 A IT MI20030237A IT MI20030237 A1 ITMI20030237 A1 IT MI20030237A1
Authority
IT
Italy
Prior art keywords
conglutin gamma
treatment
lupin conglutin
lupin
gamma
Prior art date
Application number
IT000237A
Other languages
English (en)
Inventor
Marcello Duranti
Paolo Morazzoni
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Priority to IT000237A priority Critical patent/ITMI20030237A1/it
Priority to SI200430714T priority patent/SI1605957T1/sl
Priority to KR1020057014390A priority patent/KR101084434B1/ko
Priority to PL377578A priority patent/PL214193B1/pl
Priority to RU2005125411/15A priority patent/RU2339393C2/ru
Priority to AU2004212297A priority patent/AU2004212297B2/en
Priority to AT04708771T priority patent/ATE391510T1/de
Priority to US10/545,103 priority patent/US7323441B2/en
Priority to CA2515607A priority patent/CA2515607C/en
Priority to PCT/EP2004/001111 priority patent/WO2004071521A1/en
Priority to EP04708771A priority patent/EP1605957B1/en
Priority to JP2006501760A priority patent/JP2006517212A/ja
Priority to CN2004800039114A priority patent/CN1747739B/zh
Priority to KR1020117005984A priority patent/KR20110033312A/ko
Priority to HK06106013.4A priority patent/HK1085927B/xx
Priority to DK04708771T priority patent/DK1605957T3/da
Priority to DE602004012984T priority patent/DE602004012984T2/de
Priority to ES04708771T priority patent/ES2303937T3/es
Priority to PT04708771T priority patent/PT1605957E/pt
Publication of ITMI20030237A1 publication Critical patent/ITMI20030237A1/it
Priority to IL170200A priority patent/IL170200A/en
Priority to NO20053788A priority patent/NO333224B1/no
Priority to CY20081100628T priority patent/CY1108138T1/el
Priority to JP2012100564A priority patent/JP5504301B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
IT000237A 2003-02-11 2003-02-11 Uso della conglutina di lupino per il trattamento del ITMI20030237A1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT000237A ITMI20030237A1 (it) 2003-02-11 2003-02-11 Uso della conglutina di lupino per il trattamento del
CN2004800039114A CN1747739B (zh) 2003-02-11 2004-02-06 羽扇豆球蛋白用于制备治疗ⅱ型糖尿病的药物、食品补充剂或食品的用途
JP2006501760A JP2006517212A (ja) 2003-02-11 2004-02-06 Ｉｉ型糖尿病の治療のためのルーピンコングルチンの使用
PL377578A PL214193B1 (pl) 2003-02-11 2004-02-06 Zastosowanie konglutyny gamma lubinu do wytwarzania leku do leczenia cukrzycy typu II, jako czynnika terapeutycznego i hipoglikemizujacego oraz farmaceutyczne lub zywieniowe kompozycje zawierajace konglutyne gamma lubinu
RU2005125411/15A RU2339393C2 (ru) 2003-02-11 2004-02-06 Применение конглютина для лечения диабета ii типа
AU2004212297A AU2004212297B2 (en) 2003-02-11 2004-02-06 The use of lupin conglutin for the treatment of type II diabetes
AT04708771T ATE391510T1 (de) 2003-02-11 2004-02-06 Verwendung eines lupinkonglutins für die behandlung von diabetes typ ii
US10/545,103 US7323441B2 (en) 2003-02-11 2004-02-06 Use of lupin conglutin for the treatment of type II diabetes
KR1020117005984A KR20110033312A (ko) 2003-02-11 2004-02-06 Ⅱ형 당뇨병 치료용 루핀 콘글루틴의 용도
KR1020057014390A KR101084434B1 (ko) 2003-02-11 2004-02-06 Ⅱ형 당뇨병 치료용 루핀 콘글루틴의 용도
EP04708771A EP1605957B1 (en) 2003-02-11 2004-02-06 The use of lupin conglutin for the treatment of type ii diabetes
SI200430714T SI1605957T1 (sl) 2003-02-11 2004-02-06 Uporaba lupinskega konglutina za zdravljenje diabetesa tipa ii
PCT/EP2004/001111 WO2004071521A1 (en) 2003-02-11 2004-02-06 The use of lupin conglutin for the treatment of type ii diabetes
CA2515607A CA2515607C (en) 2003-02-11 2004-02-06 Use of lupinus albus conglutin gamma for the treatment of type ii diabetes
HK06106013.4A HK1085927B (en) 2003-02-11 2004-02-06 The use of lupin conglutin for the preparation of a medicament, food supplements or foods for the treatment of type ii diabetes
DK04708771T DK1605957T3 (da) 2003-02-11 2004-02-06 Anvendelse af lupin-konglutin til behandling af type II-diabetes
DE602004012984T DE602004012984T2 (de) 2003-02-11 2004-02-06 Verwendung eines lupinkonglutins für die behandlung von diabetes typ ii
ES04708771T ES2303937T3 (es) 2003-02-11 2004-02-06 Uso de conglutina de altramuz para el tratamiento de diabetes tipo ii.
PT04708771T PT1605957E (pt) 2003-02-11 2004-02-06 Utilização de conglutina de tremoço para o tratamento de diabetes do tipo ii
IL170200A IL170200A (en) 2003-02-11 2005-08-10 Use of lupin conglutin for the preparation of a medicament for the treatment of type ii diabetes
NO20053788A NO333224B1 (no) 2003-02-11 2005-08-10 Anvendelse av lupin-konglutin gamma for behandling av type II diabetes og farmasoytiske eller ernaeringssammensetninger inneholdene lupin-konglutin gamma.
CY20081100628T CY1108138T1 (el) 2003-02-11 2008-06-12 Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
JP2012100564A JP5504301B2 (ja) 2003-02-11 2012-04-26 Ｉｉ型糖尿病の治療のためのルーピンコングルチンの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000237A ITMI20030237A1 (it) 2003-02-11 2003-02-11 Uso della conglutina di lupino per il trattamento del

Publications (1)

Publication Number Publication Date
ITMI20030237A1 true ITMI20030237A1 (it) 2004-08-12

Family

ID=32866063

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000237A ITMI20030237A1 (it) 2003-02-11 2003-02-11 Uso della conglutina di lupino per il trattamento del

Country Status (20)

Country Link
US (1) US7323441B2 (it)
EP (1) EP1605957B1 (it)
JP (2) JP2006517212A (it)
KR (2) KR101084434B1 (it)
CN (1) CN1747739B (it)
AT (1) ATE391510T1 (it)
AU (1) AU2004212297B2 (it)
CA (1) CA2515607C (it)
CY (1) CY1108138T1 (it)
DE (1) DE602004012984T2 (it)
DK (1) DK1605957T3 (it)
ES (1) ES2303937T3 (it)
IL (1) IL170200A (it)
IT (1) ITMI20030237A1 (it)
NO (1) NO333224B1 (it)
PL (1) PL214193B1 (it)
PT (1) PT1605957E (it)
RU (1) RU2339393C2 (it)
SI (1) SI1605957T1 (it)
WO (1) WO2004071521A1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030237A1 (it) * 2003-02-11 2004-08-12 Indena Spa Uso della conglutina di lupino per il trattamento del
CA2726231A1 (en) 2008-05-30 2009-12-03 Fondazione Centro San Raffaele Del Monte Tabor Uses of conglutin-y
EP2411137B1 (en) 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
AU2011315525B2 (en) 2010-10-12 2016-05-12 Consumo Em Verde - Biotecnologia Das Plantas, S.A. Antimicrobial protein
CA2953644C (en) * 2014-06-30 2020-08-11 Prolupin Gmbh Emulsion with lupine protein
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU66892A (sh) * 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
JPH08127538A (ja) * 1994-10-31 1996-05-21 Masakiyo Takahashi 糖尿病治療薬
JPH0967252A (ja) * 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
ITMI20030237A1 (it) * 2003-02-11 2004-08-12 Indena Spa Uso della conglutina di lupino per il trattamento del

Also Published As

Publication number Publication date
IL170200A (en) 2010-05-31
JP5504301B2 (ja) 2014-05-28
NO333224B1 (no) 2013-04-15
KR20110033312A (ko) 2011-03-30
KR20050106415A (ko) 2005-11-09
RU2005125411A (ru) 2006-01-27
PL377578A1 (pl) 2006-02-06
AU2004212297A1 (en) 2004-08-26
EP1605957B1 (en) 2008-04-09
CN1747739A (zh) 2006-03-15
US7323441B2 (en) 2008-01-29
PL214193B1 (pl) 2013-06-28
RU2339393C2 (ru) 2008-11-27
JP2006517212A (ja) 2006-07-20
WO2004071521A1 (en) 2004-08-26
CY1108138T1 (el) 2014-02-12
DE602004012984D1 (de) 2008-05-21
NO20053788D0 (no) 2005-08-10
US20060142185A1 (en) 2006-06-29
NO20053788L (no) 2005-11-11
PT1605957E (pt) 2008-06-27
HK1085927A1 (en) 2006-09-08
JP2012153715A (ja) 2012-08-16
AU2004212297B2 (en) 2009-09-10
CN1747739B (zh) 2013-04-17
KR101084434B1 (ko) 2011-11-21
DE602004012984T2 (de) 2009-06-04
CA2515607C (en) 2013-10-15
CA2515607A1 (en) 2004-08-26
ES2303937T3 (es) 2008-09-01
DK1605957T3 (da) 2008-08-11
SI1605957T1 (sl) 2008-08-31
ATE391510T1 (de) 2008-04-15
EP1605957A1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
BR0308799A (pt) co-glóbulos de dha e alecrim e método de uso
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
CY1108033T1 (el) Βελτιωμενη παιδιατρικη συνθεση και μεθοδοι για την παροχη τροφης και τη βελτιωση της ανεκτικοτητος
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
DK1455603T3 (da) Stimulering af in vivo produktion af proteiner med en formulering, der omfatter leucin
HK1049431A1 (zh) 用於增加肌肉塊和力量的食物補充方法
MX2008004734A (es) Composicion rica en leucina.
GEP20063818B (en) Orodispersible pharmaceutical composition comprising agomelatine
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
PL378238A1 (pl) Związki biaromatyczne, które aktywują receptory typu PPAR<$Egamma>, oraz ich zastosowanie w kompozycjach kosmetycznych albo farmaceutycznych
BR0308713A (pt) Co-esférula de dha e alecrim, e métodos de uso
AU2003207417A1 (en) Use of tryptophan rich peptides
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
EP1173476A4 (en) SOYBEAN PROTEIN NUTRIENTS
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
PL368686A1 (en) Novel aminobenzoephenones
AR045745A1 (es) Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades mediadas por cox-2
WO2002089741A3 (en) Compositions and methods for enhancing drug delivery
SI1581239T1 (sl) Zgodnja uporaba ekstrakta listov rdeče vinske trte
MX2009012599A (es) Mutantes de vegf-d y su uso.
MY184130A (en) Peptidic growth hormone secretagogues analog compounds and preparations thereof
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
DK1644402T3 (da) Arginin/lysin-berigede peptider